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Abstract
Different data indicate that psychological and/or emotional disorders may play an important role in the natural 
history of heart diseases. Although the major evidence is that related to depression, epidemiological data would indicate 
that anxiety and panic disorders are highly represented in cardiac patient, thus influencing mortality and morbidity.
The diagnosis of panic disorder in patients with chest pain is crucial to a correct therapeutic approach, as well as to 
reduce the risks and costs of inappropriate treatments. 
Anxiety and panic may accelerate different direct and indirect processes involved in the pathogenesis of 
cardiovascular diseases: lifestyle risk factors, arterial hypertension, myocardial perfusion, autonomic nervous system or 
hypothalamus-pituitary-adrenal axis, platelet activation, and inflammation processes. Panic disorder seems to correlate 
particularly with sudden death: this suggests that it may be considered one of the main inducers of life-threatening 
arrhythmias, rather than to be linked to the development and progression of coronary atherosclerosis. 
Beyond hard outcomes, panic disorders produce negative effects on both global adjustment and life quality that 
may impair the course of the cardiac diseases. Interestingly, specific antipanic and anxiolytic agents seem to be 
particularly effective upon life quality. In any case, adequate controlled clinical trials are necessary in order to confirm 
the possibility of cardiovascular risk reduction by means of anxiety and panic disorder treatment.
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 Introduction
Anxiety disorders represent the most prevalent 
psychiatric disorders, with a considerable burden 
associated with them, not only for individual sufferers, 
but also for the health care system. A milestone in 
this field was represented by the Donald Klein’s 
recogniton of panic disorder (Klein 1981), its inclusion 
in the standard diagnostic systems (ICD or DSM-5), 
and subdivision into distinct entities until the latest 
nosological standardization (DSM-5). 
Generally, anxiety disorders show an early onset 
and, as such, impair school and work performances, and 
later psychosocial functioning (Martin 2003). Although 
the traditional opinion was that that most anxiety 
disorders do not last too long, prospective studies 
suggest they are amongst the most chronic conditions 
(Martin 2003). 
Anxiety disorders are very frequent in community 
settings, as well as in primary and secondary medical 
care, with a lifetime prevalence of about 25% (Katzman 
2007). In the USA, anxiety disorders affect 20 million 
people yearly, and in other countries the prevalence is 
almost the same (Schulman 2005). 
Panic disorder is one of the most frequent anxiety 
disorders (American Psychiatric Association 2013), 
with higher rates in women than men. The National 
Comorbidity Survey reported an annual prevalence of 
2.2%, and a lifetime prevalence of 22.7% (Kessler et 
al 2006) Recently, there has been a dramatic increase 
in rates of panic attacks from 5.3% to 12.7% (Chen et 
al. 2009). Panic disorder is a condition characterized by 
recurring severe panic attacks. These attacks typically 
last about 10-15 minutes, but can be as short-lived as 1–5 
minutes and last as long as 30 minutes or until medical 
intervention. However, attacks can wax and wane for a 
period of hours (panic attacks rolling into one another), 
and the intensity and specific symptoms of panic may 
vary over the duration. Common symptoms of an attack 
include rapid heartbeat, perspiration, dizziness, dyspnea, 
trembling, uncontrollable fear and hyperventilation. 
Other symptoms are sweating, shortness of breath, 
sensation of choking, chest pain, nausea, numbness 
or tingling, chills or hot flashes, and some sense of 
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Coronary heart disease
Coronary heart disease is the most frequent cardiac 
disease and, together with stroke, represents the first 
cause of death and disability in the world. Angina 
pectoris and myocardial infarction are its main forms 
(Bonow et al. 2012).
Angina is characterized by a thoracic, retrosternal 
pain, often irradiated to the neck or to the arms, 
perceived as oppressive or constrictive, and sometimes 
accompanied by breathlessness, algid sweating, 
tachycardia, paleness, anxiety, nausea, vomit and the 
sensation of imminent death. Blood pressure values 
may be high, and a marked bradycardia may also be 
present. The duration of these symptoms may vary from 
one to 20 minutes. 
Angina may manifest itself in different forms: 
stable, unstable, Prinzmetal, and X syndrome (Bonow 
et al. 2012). Stable angina occurs after physical or 
emotional stress, and is due to the presence of a fixed 
coronary stenosis allowing, at rest, a normal coronary 
flow that becomes insufficient, causing myocardial 
ischemia, when oxygen requests augment. With rest 
ischemia ends, thus no cardiac damage is present. The 
electrocardiogram may be normal, whereas during an 
ergometer stress test or a dynamic electrocardiographic 
recording, alterations of the ST-T segment may occur, 
normalizing themselves with rest. Also, defects in 
Thallium or Technetium radionuclides captation shown 
up by the myocardial scintigraphy, or abnormalities 
of the cardiac cynesis by the echocardiogram during 
exercise or pharmacologic stress may manifest 
themselves, disappearing at rest. 
Unstable angina may occur also at rest, and is 
generally the expression of an unstable coronary plaque; 
this form is more severe, as it may evolve towards a 
myocardial infarction. Also variant, or Prinzmetal 
angina occurs at rest, with a typical, transitory ST 
segment elevation at the electrocardiogram; this form is 
consequent to a spasm in an otherwise normal coronary 
artery, thus it is more benign than the unstable one. 
Also in X syndrome no significant coronary stenosis is 
observed, notwithstanding the presence of both angina 
and electrocardiogram changes (without ST segment 
elevation) at rest or during stress. Finally, a transitory 
myocardial ischemia with electrocardiogram changes, 
due to coronary atherosclerosis, may also be observed 
in absence of chest pain (silent ischemia), particularly 
in diabetic patients, whose pain threshold is reduced.
Acute myocardial infarction is a clinical syndrome 
consequent to a total or subtotal occlusion of a coronary 
vessel, often due to a thrombus superimposed on an 
unstable coronary plaque, causing a severe, prolonged 
(more than 20 minutes) reduction of the coronary flow 
(Bonow et al. 2012). The consequent acute ischemia 
determines myocardial cell necrosis (releasing cardiac 
enzymes and troponins into the blood flow); the damage 
to myocardial tissue is thus irreversible, without 
restitutio ad integrum. This may even lead to arrhythmic 
sudden death or left ventricular pump dysfunction, with 
consequent congestive heart failure. The symptoms of 
acute myocardial infarction are analogous, although 
more prolonged and severe than those of angina. The 
electrocardiogram may exhibit an ST segment elevation 
in the case of total occlusion, and an ST segment 
depression or other alterations (including a normal 
aspect) in the case of subtotal occlusion. Elevation of 
cardiac enzymes and troponins is thus often necessary 
in order to confirm the diagnosis.
altered reality. In addition the person usually has some 
thoughts of impending doom. Individuals suffering 
from an episode have often a strong wish of escaping 
from the situation that provoked the attack. It may also 
include significant behavioral change lasting at least a 
month and ongoing worries about the implications or 
concerns about developing other attacks.
Panic disorder has been long associated with an 
increased risk for other psychiatric disorders, and also 
of heart diseases (Schulman et al. 2005). 
This review aims to deal with the complex 
relationship between anxiety, with a specific focus on 
panic disorder, and cardiovascular diseases, in particular 
cardiac arrhythmias and coronary heart disease.
Anxiety and panic disorder
Intense anxiety with sudden onset and brief duration 
characterizes a panic attack (American Psychiatric 
Association 2013). In particular, a panic attack is a 
paroxysmal episode of anxiety occurring abruptly, 
reaching its maximal intensity in a few minutes and 
with a duration of about ten minutes. Subjectively, 
the patient experiences anxiety not psychologically 
derivable, during which concomitant sensations 
of impotence, imminent catastrophe and extreme 
discomfort are present, often resulting in fear of dying, 
becoming mad, or losing control of one’s actions. 
(American Psychiatric Association 2013). 
According to the DSM-5, to diagnose a panic attack 
requires the presence or four (or more) of the somatic 
and cognitive symptoms listed in table IIa, occurring 
abruptly and having their peak within about 10 minutes. 
In the latest DSM-5, panic attacks are no longer related 
to agoraphobia but function as a marker and prognostic 
factor for severity of diagnosis, course, and comorbidity 
across an array of disorders, including (but not limited 
to) anxiety disorders; hence, the panic attack became a 
specifier for all DSM-5 disorders (American Psychiatric 
Association 2013). 
Expected panic attacks are those that occur due to 
a specific fear, such as when a person with a fear of 
flying is on an airplane. Unexpected panic attacks occur 
suddenly or unexpectedly, without any external cue that 
the attack is about to occur.
When individuals suffer from recurrent panic 
attacks, they may be diagnosed as patients with a panic 
disorder, the main symptom being the experience of 
persistent and typically unanticipated panic attacks. 
The diagnostic criteria also specifies that these panic 
attacks are marked by continual fear of having future 
attacks, shifts in one’s behavior to avoid these attacks, 
or both of these issues for at least one month (American 
Psychiatric Association 2013). Finally, anxiety 
sensitivity is the fear of bodily sensations associated 
with anxiety (Taylor 1995). People with higher anxiety 
sensitivity tend to overinterpret and catastrophize 
in response to sensations such as sweaty palms, 
shallow breathing, rapid pulse, and other symptoms 
accompanying stress, which can be perceived as 
warnings of impending doom. Anxiety sensitivity is 
a relatively constant personality factor, distinct from 
anxiety itself, which fluctuates with events (Olatunji 
and Wolitzky-Taylor 2009). Most research on anxiety 
sensitivity has focused on panic disorder (Taylor 2006). 
Patients with panic disorder have higher scores than 
normal individuals on anxiety sensitivity measures, and 
conversely people with higher anxiety sensitivity are 
more likely to have panic attacks (McNally 2002).
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(Katerndahl 2004) (table IIa), as 3 other symptoms 
are needed to confirm the diagnosis. The prevalence 
of panic disorders is high (about 57%) in patients 
with non-cardiac chest pain, i.e. atypical, without 
electrocardiogram changes and associated to normal 
coronary arteries (Soh and Lee 2010). Many patients 
admitted to an emergency care unit for a suspected 
acute coronary syndrome could suffer from a panic 
attack. Even among patients with a previous history 
of cardiovascular disease who are referred to medical 
attention for non-ischemic (parietal or oesophageal) 
chest pain, the prevalence of panic disorder is 34% 
(Fleet et al. 2005). 
Patients with panic attacks and chest pain fear 
illness and death so much (Katerndahl 2004) that they 
easily request medical assistance. Indeed, patients with 
higher anxiety sensitivity pay more attention to their 
heartbeats and heart rate (Stewart et al. 2001) and to 
the electrocardiogram, relating their symptoms to an 
ischemic heart disease (Katerndahl 2004). Chest pain 
during a panic attack is thus related with hospitalization 
(Fleet et al. 2005) and to the fruition of the assistance 
of family doctors, psychiatrists and cardiologists. 
Physicians and non-psychiatric specialists very often 
underestimate this psychiatric condition in patients with 
a history of recurrent chest pain and without a coronary 
atherosclerotic disease (Katerndahl 2004), and this may 
lead to inappropriate treatments and avoidable costs. A 
high number of patients with no atherosclerotic disease 
of the coronary arteries, but rather affected by a panic 
disorder, underwent coronary angiography (Katerndahl 
2004). 
Commonly patients with non-cardiac chest pain 
who are diagnosed with panic disorders are reassured 
and referred back to primary care, leaving them 
undiagnosed and untreated. However, the presence 
of chest pain during a panic attack seems to be also 
related to the severity of the psychiatric disease (with 
possible suicidal thoughts) (Fleet et al. 2005) and to a 
lower quality of life (Katerndahl 2004). Thus, patients 
presenting noncardiac chest pain should be screened 
for psychopathology. Identifying these patients 
might be useful to establish ad hoc interventions, 
i.e. brief cognitive behavioral therapy sessions, or 
pharmacological treatment, while improving patients’ 
morbidity with superior incremental cost-effectiveness 
ratios (Marchand et al. 2012, Poirier-Bisson et al. 2013, 
Buccelletti et al. 2013, Van Beek et al. 2013).
The diagnosis of panic disorders in patients with 
chest pain is crucial not only to a correct treatment, but 
also to reduce the risks and costs of inappropriate and 
unnecessary treatments, although there are no exact 
data of the costs of health care related to panic disorders 
and mistakenly attributed to heart disease. 
A correct aetiological diagnosis of chest pain during 
a panic attack is often difficult in the emergency care 
unit (Fleet et al. 2005), although it is easier for the 
general practitioners, who know their patients and 
their psychological habits (Aikens et al. 1998). Some 
“atypical” characteristics of the chest pain may suggest 
a panic disorder (table IIa-b). An atypical pain without 
evidence of atherosclerotic coronary disease has 
high probability of deriving from a panic disorder. In 
general, we should suspect panic disorder in patients 
with chest pain in the presence of young age, female 
gender, atypical pain, absence of organic diseases, 
or mitral valve prolapse. The relief of pain after the 
administration of sublingual nitrates does not, per se, 
rule out panic disorders, that are often associated with 
oesophageal abnormalities (i.e. oesophageal spasm) 
(Soh and Lee 2010). Anxiolytic and placebo drugs may 
Arrhythmias
The term cardiac arrhythmia covers a wide range 
of different conditions due to heart rhythm disorders, 
in which the cardiac electrical activity is irregular, 
or faster (over 100 beats per minute) or slower (less 
than 60 beats per minute) than normal (Bonow et al. 
2012). The most common symptom of arrhythmia is an 
abnormal awareness of heartbeat, called palpitations. 
Also, when the heartbeat is too fast, too slow or too 
weak to supply the body's needs, it manifests itself as 
a lower blood pressure and may cause lightheadedness, 
dizziness, or syncope. Direct assessment of the 
abnormality using an electrocardiogram is the main way 
to diagnose any cardiac rhythm disorder. Arrhythmias 
can occur in the upper (atria) or in the lower chambers 
of the heart (ventricles). Atrial fibrillation is the most 
common arrhythmia (Bonow et al. 2012). In this form, 
the normal regular electrical impulses generated by 
the sino-atrial node are overwhelmed by disorganized 
electrical impulses, usually originating in the roots of 
the pulmonary veins, leading to the irregular conduction 
of ventricular impulses that generate the heartbeat. 
Atrial fibrillation may occur in episodes lasting from 
minutes to days ("paroxysmal") or may be permanent. 
It may cause no symptoms, but it is often associated 
with symptoms related to a rapid, uncoordinated heart 
rate (the heart being unable to provide adequate blood 
flow and oxygen delivery to the rest of the body) that 
may be perceived as palpitations, fainting, or exercise 
intolerance and occasionally may produce chest 
discomfort or even angina (if the faster rate puts the 
heart under strain) as well as congestive symptoms of 
shortness of breath or even acute pulmonary oedema. 
It may be identified clinically when taking a pulse; 
a heart examination will reveal an irregular, rapid 
rhythm and its presence must be confirmed with an 
electrocardiogram showing the absence of p waves with 
disorganized electrical activity in their place, and an 
irregular ventricular rate due to the irregular conduction 
of impulses to the ventricles. Atrial fibrillation may be 
treated with medications aimed at either slowing the 
heart rate to a normal range ("rate control") or reverting 
the heart rhythm to normal ("rhythm control").
Supraventricular ectopic beats also originate in 
the atria and when repeated present themselves as a 
supraventricular paroxysmal tachycardia (Bonow et al. 
2012), that may generate symptoms like those of atrial 
fibrillation. Supraventricular arrhythmias are, however, 
normally harmless (although disturbing for patients).
In contrast, some ventricular arrhythmias can be 
more dramatic. Ventricular tachycardia or fibrillation 
are always a life-threatening medical emergency 
(Bonow et al. 2012). When the heart goes into 
ventricular fibrillation, effective pumping of the blood 
stops (cardiac arrest). If left untreated, ventricular 
fibrillation can lead to death within minutes.
Differential diagnosis
To distinguish between a panic attack and an acute 
coronary syndrome is particularly complex, due to 
the overlapping of the clinical-symptomatic pattern, 
as shown in table IIa-b. Panic disorders, previously 
described as “cardiac neurosis, irritable cardiac 
syndrome or soldier’s heart”, are commonly associated 
with symptoms such as chest pain, tachycardia, and 
dyspnoea. In particular, chest pain is so frequent among 
patients with panic disorder that it is considered as one 
of its 14 diagnostic, albeit non pathognonomic criteria 
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et al. 1999) (whereas the prevalence of panic attacks in 
the general population is about 2%) (Frommeyer et al. 
2012). Last, but not least, it is known that significant 
anxiety disorders can persist even after an acute phase 
of coronary syndromes (Grace et al. 2004). It has been 
estimated that almost 55% of the candidate patients for 
aortic-coronary bypass have high levels of anxiety in 
the preoperative period, which remain high in 32% of 
cases in the three following months (Pignay-Demaria et 
al. 2003).
Anxiety and panic are observed also in cardiovascular 
diseases other than coronary heart disease. In a 
recent survey on a German general population, in 
which 12-month prevalence of psychiatric disorders 
was assessed through the Composite International 
Diagnostic Interview, panic disorder was associated 
with cerebrovascular disease (adjusted OR 2.28; 95 % 
CI 1.09-4.77) and peripheral vascular diseases (adjusted 
OR 2.97; 95 % CI 1.55-5.69) (Tully and Baune 2013). 
Few data are currently available regarding prevalence of 
anxiety disorders in heart failure (MacMahon and Lip 
2002). In the SOLVD study, women with heart failure 
had levels of anxiety higher than neoplastic controls 
(Riedinger et al. 2002). Panic disorders have also been 
associated with aortic aneurisms (Benjamin et al. 2000), 
pulmonary hypertension (Sietsema et al. 1987), and, in 
particolar, with mitral valve prolapse, although this is 
not clearly proven (Katerndahl 1993). The important 
overlapping of symptoms between panic disorder and 
this latter condition may be related to an autonomic 
dysfunction. Probably the reduction in left ventricular 
volume, that is consequent to tachycardia (common in 
panic disorder), may cause a functional and reversible 
mitral valve prolapse (Katerndahl 1993). Finally, in 
spite of improved survival of patients with implantable 
cardiac defibrillators, their electric discharges may 
induce unexpected discomfort and are associated with a 
high rate of anxiety symptoms (Burg et al 2004). 
In general, thus, there is a large consensus that 
cardiac patients show a high prevalence of psychiatric 
comorbidities with anxiety disorders, in particular panic 
(27%) and generalized anxiety disorders (GAD, 5-30%) 
(Bankier et al. 2004, Konstam et al. 2005; (Schulman et 
al. 2005). Lower values of absolute prevalence of panic 
disorder (although frequently coexistent with GAD) in 
patients with cardiovascular diseases have been detected, 
in contrast, by using brief screening tools, such as the 
GAD-2 scale (Celano et al. 2013). Commonly, in fact, 
patients with chronic heart diseases have at least two 
associated psychiatric disorders (Bankier et al. 2004).
Panic disorder as a trigger of acute cardiac 
events
Acute psychosocial stressors (events that require 
individual adaptive reaction within minutes, hours or 
days), like excitement, catastrophes, terroristic attacks, 
wars, earthquakes, and bereavements, can trigger a 
sudden cardiac event (Tennant and McLean 2001, Strike 
and Steptoe 2005, Davidson 2008). Data regarding 
trigger events can be obtained from retrospective studies 
or from prospective electronic daily records correlated 
with outpatient electrocardiogram recording or 
implantable cardiac defibrillators. A meta-analysis has 
suggested that an emotional stress precedes a myocardial 
infarction in 7% of cases, especially in women (Culic et 
al. 2005).
Some years ago a new cardiomyopathy was defined 
whose clinical presentation is very similar to an acute 
coronary syndrome, with electrocardiographic changes 
reduce the recurrence of pain in patients with normal 
coronary arteries. When the pain has a prolonged 
duration, negativity of cardiac enzymes and troponins 
may exclude acute coronary syndromes. Viceversa, 
when symptoms are of short duration, a stress 
ergometer electrocardiogram or imaging test must be 
performed to exclude forms of angina pectoris. Many 
psycho-diagnostic tests (Panic Disorder Module of the 
Structured Clinical Interview, Quick PsychoDiagnostic 
Panel, etc.) allow emergency care unit physicians 
to make diagnosis of panic disorders (Halgren et 
al. 2007; Foldes-Busque et al. 2011). Agoraphobia 
and hypocalcaemia (or its indirect signs, like those 
of Chvostek and Trosseau), which is subsequent to 
hyperventilation, may be useful to orientate diagnosis. 
However, the presence of panic disorder does not 
exclude a concomitant coronary disease, thus it has the 
important role of inducing these patients to look for 
medical assistance.
As regards cardiac arrhythmias, anxiety and panic 
symptoms such as a racing or pounding heartbeat, 
dizziness, light-headedness, nausea, difficulty in 
breathing, tingling or numbness in the hands, flushes 
or chills, may be similar to those of atrial fibrillation 
or supraventricular and ventricular ectopic beats 
or tachycardia, i.e. paroxysmal supraventricular 
tachycardia (Bonow et al. 2012). Cardiac arrhythmias 
are difficult to document on the electrocardiogram, 
since they have often ceased before the patient comes 
to medical attention. Besides, a sinusal tachycardia 
may still be present and even be documented, but 
interpreted as a phenomenon secondary to the panic 
attack. When palpitations are present without evidence 
of documented arrhythmias on the electrocardiogram, a 
cardiac involvement may be excluded. In the absence 
of symptoms and electrocardiographic evidence of 
arrhythmias at the moment of medical observation, a 
24-hour dynamic electrocardiogram recording may be 
a useful tool for the differential diagnosis. However, 
the evidence that in some patients paroxysmal 
supraventricular tachycardia is the cause, but not the 
consequence, of a panic attack is based on observations 
that catheter ablation was able to cure symptoms in 
patients presenting panic disorders (Frommeyer et al. 
2012). It was thus hypothesized that a certain proportion 
of panic disorders may mutate into an underlying 
arrhythmia rather than a primary psychiatric disorder 
(Frommeyer et al. 2012).
Incidence and prevalence of panic disorder in 
heart diseases 
The onset of anxiety disorders soon after a 
cardiovascular event is very common (Moser and 
Dracup 1996, Roy-Byrne et al. 1999, Konstam et al. 
2005, Bjerkeset et al. 2005, Grace et al. 2004). In a 
recent prospective study on more than 20,000 patients, 
the incidence of anxiety symptoms was higher after a 
myocardial infarction than in the general population 
(Bjerkeset et al. 2005). As far as prevalence is concerned, 
a precise estimation of the problem is difficult, due both 
to the ample variability of clinical and instrumental 
definitions and to the different (in terms of comorbidity, 
age, gender, or socioeconomic condition) populations 
examined. In particular, the strict and immediate 
correlation between acute coronary syndromes and 
anxiety and panic disorders has been revealed in many 
studies that reported a prevalence of up to 65% for 
anxiety disorders (Moser and Dracup 1996, Grace et al. 
2004) and up to 50% for panic disorders (Roy-Byrne 
Maurizio G. Abrignani et al.
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of cardiovascular events, high levels of phobic anxiety 
were associated with the greater risk of sudden cardiac 
death, but not of non-fatal cardiovascular events (Albert 
et al. 2005). These observations suggest, as a principal 
mechanism, the induction of life-threatening arrhythmias 
rather than the development and progression of coronary 
atherosclerosis.
Patients with previous heart disease behave in a 
different way from the general population. In atrial 
fibrillation patients, anxiety sensitivity has been explored 
only as a cross-sectional correlate of lower quality of 
life and greater symptom severity and worry (Ong et 
al. 2006). More noticeably, anxiety presence in a pre-
existent acute coronary event predicts both sudden 
death and future non fatal outcomes (Frasure-Smith et 
al. 1995, Moser and Dracup 1996, Thomas et al. 1997, 
Kubzansky and Kawachi 2000, Strik et al. 2003, Pfiffner 
and Hoffmann 2004, Carpeggiani et al. 2005, Frasure-
Smith and Lespérance 2008).
Pathophysiological correlations 
Pathophysiology of panic disorders is still poorly 
understood. A number of hypotheses involve different 
cerebral areas (locus coeruleus or neuroanatomical 
model) or neurotransmitter pathways (serotonergic, 
adrenergic, lactates, carbon dioxide, and GABAergic 
models) (Freire et al. 2011). Panic disorder seems 
due, at biochemical level, to metabolic acidosis as a 
compensatory response to chronic hyperventilation. The 
described mechanism may be a triggering factor in the 
initiation of panic attacks, but many other explanations 
have been put forward (e.g. failure to control restraining 
inputs). It is supposed that anxiety and panic accelerate 
different direct and indirect processes involved in the 
pathogenesis of cardiovascular diseases: lifestyle, 
autonomic nervous system or hypothalamus-pituitary-
adrenal (HPA) axis dysregulation, reduced myocardial 
perfusion, platelet activation, and inflammation 
(Tennant and MacLean 2001).
Lifestyle risk factors, arterial hypertension, 
and subclinical atherosclerosis
Additional effects of behavioral risk factor (nicotine, 
caffeine, inadequate diet, poor adherence to treatment, 
sedentariety) must not be underestimated in anxious 
patients (Mathew et al. 2011). Not surprisingly, diabetic 
or hyperlipidemic patients show high scores on the 
Hamilton rating scales for panic or agoraphobia (Vural 
et al. 2008).
Panic disorder prevalence seems to be increased 
three-fold in essential hypertension (Esler et al. 
2008). Multiple cross sectional studies revealed a 
positive, bidirectional association between anxiety 
and hypertension; those with hypertension being more 
likely to suffer from anxiety, and viceversa. However, a 
few other studies showed no association. Longitudinal 
studies point to an increased risk of development of 
hypertension in patients who suffer from anxiety (Player 
and Peterson 2010). A negative emotional profile with 
anxiety was independently associated with arterial 
hypertension incidence in NHANES 1 (Jonas and Lando 
2000). Further, there is also evidence emerging from 
the Norwegian HUNT study (Krokstad et al. 2013) that 
this association is valid in large population samples. 
In particular, patients with panic show a significantly 
higher incidence of non-dipper blood pressure pattern 
(the lack of physiological decrease of blood pressure 
during nocturnal hours, which is a negative prognostic 
and troponin release in the absence of significant 
atherosclerotic lesions of coronary arteries (Novo et al. 
2008). It is often preceded by intense emotional stress 
and is characterized by typical wall motion abnormalities 
detectable with echocardiography. These abnormalities 
confer to the left ventricle the aspect of “Takotsubo”, 
a Japanese octopus trap. The pathophysiological 
mechanism underlying the association between stress 
and Takotsubo cardiomyopathy, however, remain yet 
to be established. Association with worse outcomes 
after heart surgery exists, being more evident in patients 
with preoperative acute anxiety than in patients with 
anxiety tracts (Pignay-Demaria et al. 2003, Nemati and 
Astaneh 2011). Indeed, preoperative stress is associated 
with haemostasis, lipids and cellular antioxidant system 
alteration with evidence of ischemia or arrhythmia at 
preoperative Holter recording (Pignay-Demaria et al. 
2003).
Panic disorder as a cardiovascular risk factor
Still more uncertain is the association between 
global cardiovascular risk and stressors (even of minor 
intensity but prolonged) as those observed in the work 
or relationship area. Anxiety in general, and specific 
disorders, such as generalized anxiety disorder or panic 
disorder, have been independently associated with 
increased risk of fatal myocardial infarction and sudden 
cardiac death in epidemiological retrospective population 
studies and prospective trials, both in healthy subjects 
(Kawachi et al. 1994a, b; Kubzansky and Kawachi 
2000; Bunker et al. 2003; Albert et al. 2005; Barger and 
Sydeman 2005; Chen et al. 2009; Scherrer et al. 2010; 
Cheng et al. 2013; Scott et al. 2013) and, particularly, 
in patients with a previous history of cardiovascular 
diseases (Frasure-Smith et al. 1995, Moser and Dracup 
1996, Thomas et al. 1997, Kuper et al. 2002, Strik et al. 
2003, Grace et al. 2004, Pfiffner and Hoffmann 2004, 
Carpeggiani et al. 2005, Huffman et al. 2008, Frasure-
Smith and Lespérance 2008, Huffman et al. 2010, 
Martens et al. 2010).
In the general population, a dose-dependent relation 
has been demonstrated: minimal signs of anxiety, and 
in particular panic disorders, are sufficient, according to 
some studies, to increase cardiovascular risk up to 5-fold 
(Kawachi et al. 1994a, b, Kubzansky and Kawachi 2000; 
Albert et al. 2005; Barger and Sydeman 2005; Chen et 
al. 2009; Scherrer et al. 2010). Finally, a recent study 
in the general population in Taiwan showed that panic 
disorders are associated with higher incidence of atrial 
fibrillation (Cheng et al. 2013). 
In a large recent survey conducted in 19 countries, 
panic disorder and specific phobia were associated, after 
comorbidity adjustment, with heart disease onset (ORs 
1.3-1.6) (Scott et al. 2013). In contrast, some systematic 
reviews on this matter (Kuper et al. 2002, Bunker et 
al. 2003) failed to report any casual and independent 
association between anxiety (or panic disorders) and 
coronary risk. By contrast, different epidemiological 
studies demonstrated a significant relation between 
anxiety disorders and sudden cardiac death. The Health 
Professional Study reported a 6-fold increase of sudden 
death in healthy men with phobic anxiety, as defined 
by using Crown-Crisp Anxiety Index (Kawachi et al. 
1994a). In the Normative Aging Study (Kawachi et al. 
1994b), anxiety was associated with a 1.9-fold increase 
of fatal cardiovascular events and with a significantly 
greater 4.7-fold increase of sudden death in a 32-
year follow up. Even in the Nurses’ Health Study, that 
analyzed about 700,000 women without previous history 
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attacks with chest pain. Postmenopausal women with 
a recent history of panic attacks, by contrast, do not 
appear to have more daily life ischemia, as measured by 
occurrence of ST depression during 24-hour monitoring, 
but do show more chest pain and possibly lower heart 
rate variability, suggesting that even sporadic panic 
attacks may be related to cardiovascular risk (Smoller 
et al. 2006).
Mediated effects of the autonomic nervous 
system dysregulation
Increased activity of the sympathetic nervous system 
and reduced parasympathetic activity are invoked as 
important mechanisms bridging stress and ischemic 
heart disease (Samuels 2007). Clinical research in this 
area uses evaluations of plasmatic catecholamines and 
heart rate variability (HRV).
Patients with anxiety or panic disorder and 
heart disease show an excessive systemic response 
to stress, characterized by persistent stress-related 
changes in sympathetic nerve biology with augmented 
catecholamine production (Samuels 2007), which in 
turn lead to elevation in the heart rate, systolic and 
diastolic blood pressure, and vascular resistance, with a 
consequent increase in myocardial oxygen request (Fleet 
et al. 2005). In particular, patients with panic disorder 
and those with hypertension show similar patterns (Esler 
et al. 2008, Jonas and Lando 2000): in both, epinephrine 
cotransmission is present in sympathetic nerves. Single-
fibre sympathetic nerve firing spikes (spikes of multiple 
firings within a cardiac cycle) occur; tissue nerve growth 
factor (a stress index) is increased; there is induction 
of phenylethanolamine N-methyltransferase (that 
synthesizes in situ epinephrine) in sympathetic nerves; 
finally, there is activation of noradrenergic brain stem 
neurons projecting to the hypothalamus and amygdala. 
These pathophysiological findings strongly support the 
view that panic disorders and chronic mental stress with 
autonomic nervous system dysfunction are important in 
the pathogenesis of essential hypertension (Jonas and 
Lando 2000). 
A hypothesis now under testing is whether in both 
disorders, under prevailing conditions of ongoing 
stress, phenylethanolamine N-methyltransferase acts as 
a DNA methylase, causing the silencing norepinephrine 
transporter gene that is present in both conditions 
(Esler et al. 2008). Panic symptoms of autonomic 
origin such as sweating and flushes, indeed, are more 
common in attacks experienced by hypertensive than 
by normotensive patients (Davies et al. 2008). After 
hyperventilation, patients with panic disorder and GAD 
demonstrated also a greater heart rate than that of control 
subjects (Pittig et al. 2012). In addition, adrenergic 
effects on platelet aggregation, vascular reactivity and 
permeability may reduce coronary perfusion (Jonas 
and Lando 2000). Particularly in patients with atrial 
fibrillation and chronic heart failure who have high 
anxiety sensibility, heightened awareness of anxiety 
symptoms including palpitations and heart rate changes 
may increase fear, augmenting physiological sensations 
and thoughts of catastrophe, increasing sympathetic 
arousal, catecholamine levels, and heart rate in a 
vicious cycle, and potentially increasing arrhythmic 
risk (Frasure-Smith et al. 2012).
HRV (described as standard deviation of RR 
intervals at electrocardiographic recording), that is 
controlled, centrally, from the hypothalamus and the 
limbic system and, peripherally, from vagus nerve, 
can be utilized as an index of the ability to maintain 
index) than control subjects (Alici et al 2013). 
The negative effects on all of these risk factors 
may explain the observed association between anxiety 
and panic and subclinical markers of atherosclerosis 
(Seldenrijk et al. 2010 and 2012). In the Netherlands 
Study of Depression and Anxiety, a large cohort of 
patients with anxiety disorders (social phobia, GAD, 
panic disorder, agoraphobia) was compared to non-
anxious control subjects. Higher scores of anxiety 
sensitivity, measured by the Anxiety Sensitivity Index, 
were associated with both increased likelihood of 
carotid plaques using B-mode ultrasonography (OR per 
SD increase=1.34, 95%CI=1.06-1.68) and increased 
central arterial hardening (augmentation index) using 
calibrated radial applanation tonometry (p=.01). These 
observations suggest that vulnerability to anxiety, rather 
than to depression, represents a correlate of subclinical 
atherosclerosis (Seldenrik et al 2012). Also, patients 
with current (i.e., past year) anxiety or comorbid 
depressive and anxiety disorders showed two- to three-
fold increased odds of low (<or=0.90) ankle-brachial 
Index (Seldenrik et al 2012). Moreover, carotid-femoral 
pulse wave velocity, the gold standard measurement of 
arterial hardening, is increased in patients with panic 
disorder (Cicek et al. 2012).
Myocardial perfusion
Some anxiety effects on the heart are considered 
consequences of an excessive sensibility to external 
stresses. Hyperventilation, that is common in panic 
disorders, provokes an increase of cardiac output and 
contractility and it is a well known precipitant factor 
for coronary spasm that can lead, in turn, to ventricular 
arrhythmias and myocardial infarction, and also to 
the rupture of atherosclerotic plaque, both in known 
coronary patients and in apparently healthy people 
(Tennant and McLean 2001). 
Another possible ischemic mechanism in panic 
disorders is micro-vascular angina, often observed 
in women with healthy coronary arteries. Vasomotor 
abnormalities of epicardial arteries and coronary 
microcirculation were observed in coronary patients 
during mental stress (Samuels 2007). Levels of nitric 
oxide, a gas considered to play an important role in 
mediating anxiety and stress responses, with a marked 
vasodilator effect, were significantly lower in patients 
with panic depression than in control subjects (Yapislar 
et al. 2012). In turn, in patients with both panic 
disorder and heart disease, myocardial ischemia can 
favour panic attacks due to increased cerebral levels 
of cathecholamine or carbon dioxide consequent to 
lactate accumulation. In coronary heart disease patients 
with comorbid panic disorder, myocardial scintigraphy 
showed higher perfusion defects, indicative of 
myocardial ischemia, than in controls (Fleet et al. 2005). 
The same phenomenon follows induction of panic 
attack with carbon dioxide inhalation in coronary artery 
disease patients with previous positive nuclear exercise 
stress tests (Fleet et al. 2005). In contrast, in coronary 
artery disease patients with panic disorder but with 
normal exercise stress tests, a potent mental stressor, 
such as a panic challenge, induces ischemia only in a 
few patients, while suggesting that panic attacks among 
panic disorder patients with lower-risk coronary artery 
disease may not confer a risk of myocardial ischemia 
(Fleet et al. 2014). 
Other studies in patients with panic disorder show, 
by 24-hour electrocardiogram monitoring, diffuse 
abnormalities of repolarization associated to panic 
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released serotonin, produces corticotropin-releasing 
factor (CRF), stimulating the anterior pituitary to 
release adrenocorticotropic hormone (ACTH) which, 
in turn, modulates cortisol production in the adrenal 
gland (Meewisse et al. 2007). Correlations with cortisol 
activity were documented in different studies that used 
structured stress factors, like speaking in public or mental 
calculation. Chronic stimulation of the hypothalamus-
hypophysis axis can determine an increased cortisolemia 
by a negative feedback mechanism. High cortisolemia 
has been related to the development of atherosclerotic 
lesions and can determine increase of appetite as well as 
of visceral adipose tissue, weight and insulin resistance 
(Meewisse et al. 2007). These metabolic alterations 
worsen the cardiovascular risk profile (increasing 
incidence of diabetes, hypertension, dyslipidemia and 
inducing endothelial damage). Cortisol inhibits the 
growth hormone too, whose deficit (powerful stimulant 
of visceral fat) is associated to premature cardiovascular 
diseases. In addition, the hyperactivity of ACTH-
secreting hypothalamic neurons can indirectly stimulate, 
in turn, different autonomic nervous centres (Meewisse 
et al. 2007).
Altered platelet function
Platelet functions are likey to be involved (Tennant 
and McLean 2007), in particular through adrenergic 
hypersecretion, or the influence of cytokines and/or 
dysregulation on the metabolism of platelet 5-HT. In 
contrast to depressed patients, those with panic disorder 
do not show 5-HT-2 platelet receptor alterations, but 
a higher plasmatic concentration of platelet factor-4 
and beta-thromboglobulin and of augmented platelet 
aggregability (Yapislar et al. 2012). However, both 
depressed and panic disorder patients show a decreased 
number of 5-HT transporter proteins (Marazziti et 
al, 1999). In addition, platelet released 5-HT favours 
platelet aggregation and coronary vasoconstriction 
through its effect on reuptake on sites, contributing to 
endothelial damage and potentially inducing thrombotic 
events (Pignay-Demaria et al 2007). Finally, alterations 
of the fibrinolytic system (with elevated plasminogen 
activator inhibitor-1 levels) are observed in chronic 
stress.
Inflammation
Subjects with anxiety disorders show increased 
levels of inflammation markers such as leukocyte 
count, C reactive protein, interleukins, tumor necrosis 
factor, fibrinogen, and homocysteine (Brydon et al. 
2005, Yapislar et al. 2012).
Treatment
The evident negative impacts of anxiety disorders 
make it mandatory to prevent or limit personal suffering, 
economic costs, and connected social disadvantage. 
Even when panic disorder coexists with ischemic heart 
disease, patient perceived discomfort is typically more 
related to the first condition. Psychological benefits of 
anxiety treatment in coronary patients are obvious, but 
cardiovascular ones are uncertain.
Non-pharmacological treatment
Non pharmacological interventions, that can be as 
cardiovascular homeostasis. DeMeersman et al. (1996), 
studying effects of stress factors in real life (speakers 
that did a presentation alone in front of a critic 
audience), showed significant HRV changes. Spectral 
power analysis of HRV gives a valid measure of cardiac 
autonomic function, high frequency being a measure of 
the parasympathetic system and the low frequency of 
sympathetic-parasympathetic equilibrium. Reduced 
high frequency HRV, related to hypoactivity in the 
prefrontal cortex, which negatively affects executive 
functioning, is observed in patients who suffer from 
panic disorders, GAD and social anxiety (Tennant 
and McLean 2001, Hovland et al. 2012, Pittig et al. 
2013), which is consistent with the notion of autonomic 
inflexibility in anxiety disorders. Panic disorder patients 
also show more low frequency components in basal 
conditions and increased ratio between high and low 
frequency, both in basal condition and during tilt test 
(Martinez et al. 2010) or in the presence of threatening 
stimuli (Wang et al. 2013). Elevated HRV responses to 
hyperventilation, finally, are specific to panic and GAD 
(Pittig et al. 2013). A lower parasympathetic activity 
has been demonstrated in s/s carriers for the serotonin 
transporter polymorphic region (Agorastos et al. 2014). 
The s/s genotype represents a genetic vulnerability 
factor, associated with inadequate hyporeactivity to 
stress and suggests a role of the central serotonergic 
activity on the sympathoadrenal pathway. In addition, 
anxious patients develop a compromised baroreceptorial 
response, another marker of vagal control dysfunction 
(Hemingway et al. 2001).
Subjects with reduced HRV have higher risk of 
arrhythmias and sudden death, as autonomic cardiac 
function can lower the arrhythmic threshold, and this 
is specular to the observed increase of sudden death in 
anxious or panic disorder patients (Hemingway et al. 
2001). In patients with implanted cardiac defibrillators, 
predisposed to anxiety or rage, arrhythmias can be 
induced by these emotions (Burg et al. 2004). Animal 
studies give important evidence of a sudden death model 
where nervous system and ventricular arrhythmias are 
related to environmental stress factors, psychosocial 
ones in particular: in the presence of acute ischemia 
or vulnerable myocardium, stress induces ventricular 
tachycardia. This effect can be prevented by the use of 
beta-blockers (Hemingway et al. 2001). 
Acute emotive stress is the precipitant factor common 
to syncope or arrhythmia in patients with the rare genetic 
long QT syndrome (Hemingway et al. 2001). Longer 
QT intervals, which can also predispose to ventricular 
arrhythmias, were demonstrated in anxious patients. 
Toivonen et al. (1997) found lengthening of the QT 
interval in 30 healthy physicians that were subjected to 
the acute stress of an emergency call during sleep. Even 
objective QT dispersion, defined as the maximal inter-
lead difference in QT intervals on 12 leads of the surface 
electrocardiogram, reflecting the regional heterogeneity 
of ventricular repolarization, has been suggested as an 
important marker for risk of arrhythmia and sudden 
death. Q(max) and Q(min) values, as well as the mean 
corrected QT dispersion, were significantly higher in 
panic disorder patients than in healthy controls (Atmaca 
et al. 2012).
HPA axis activation 
Stress events (every situation that can lead 
to anxiety or loss of self-control) favour cortisol 
secretion (Meewisse et al. 2007). During stress, the 
hypothalamus, under the influence of amygdala-
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Pharmacological treatment
Panic disorder patients show significant psychosocial 
impairment and a high risk of psychiatric comorbidities 
and suicide. This condition should be treated effectively 
as soon as the symptoms emerge because the longer 
these patients remain without treatment, the worse the 
prognosis will be. A safe treatment in heart disease 
patients with psychoactive drugs must consider the 
cardioactive effect, pharmacological interactions and 
co-morbidity (Schulman et al. 2005, Vaccarino 2011). 
In a recent systematic review of the literature regarding 
the pharmacological treatment of panic disorder, 
selecting only open studies, placebo-controlled studies 
or comparative clinical trials, the experts considered 
as compounds with reported effectiveness in the 
treatment of panic disorders, tricyclic antidepressants, 
benzodiazepines, selective 5-HT reuptake inhibitors 
(SSRIs), and 5-HT and noradrenaline reuptake 
inhibitors (SNRIs). The last two are now the first-line 
compounds in the treatment of panic disorders, as 
these drugs were better tolerated than tricyclics and 
benzodiazepines having a low risk of dependence and 
overdosing complications (Freire et al. 2011, Batelaan 
et al. 2011, Marazziti et al. 2012). However, in the real 
world the Harvard/Brown Anxiety Research Project 
(HARP), a naturalistic, longitudinal, multisite study 
with nine years of follow-up in middle-aged and older 
adults with diagnoses of panic disorder with or without 
agoraphobia, social phobia, or GAD, has shown that 
rates of benzodiazepines use persist high among 
both the older (53% at baseline) and the younger 
(57.4%) age groups. Although there was a statistically 
significant increase in SSRI/SNRI use over time, only 
35% of participants were utilizing these medications at 
the end of the follow up, while more than one-half were 
continuing to use benzodiazepines (Benitez et al. 2008).
SSRIs
Selective SSRIs (like citalopram, dapoxetine, 
escitalopram, fluoxetine, fluvoxamine, paroxetine, and 
sertraline) are a class of compounds typically used in 
the treatment of anxiety disorders. SSRIs are believed 
to increase the extracellular level of 5-HT by inhibiting 
its reuptake into the presynaptic cell, thus increasing 
the level of the neurotransmitter in the synaptic cleft. 
They show varying degrees of selectivity for the other 
monoamine transporters, such as noradrenaline and 
dopamine transporter. SSRIs are recommended by the 
National Institute for Health and Clinical Excellence 
(www.nice.org.uk) for the treatment of GAD that 
has failed to respond to conservative measures such 
as education and self-help activities. The available 
evidence suggests that SSRIs are superior to the placebo 
in treating these forms (Kapczinski et al. 2003). There 
appears to be no significant difference in effectiveness 
between these drugs and tricyclics or benzodiazepines. 
However, SSRIs are quite tolerable in terms of side 
effects and relatively safe in suicidal overdosing. 
Further, they have fewer and milder side effects (Nardi 
et al. 2012).
Cardiovascular side effects are rare with SSRIs use. 
Due to the inhibition of different cytochrome P450 
isoenzymes, some SSRIs can alter the metabolism of 
lipophilic beta-blockers, calcium channel blockers, 
class IC anti-arrhythmic agents, and warfarin (Batelaan 
et al. 2011). SSRIs inhibit also cardiac and vascular 
sodium, calcium and potassium channels and prolong 
QT intervals, but a number of wide studies of patients 
effective as the pharmacological ones, range from pet 
therapy to cognitive behavioral educational programs 
(Januzzi et al. 2000, Sardinha et al. 2011). These, in 
particular, are a psychotherapy form based on learning 
theory, that rely on modifications of emotions and 
dysfunctional behaviour using diaries (for example 
on diet or physical exercise), and problem solving 
techniques, in order to modify the lifestyle of patients 
with chronic pathologies like obesity or diabetes, and 
in particular heart diseases, emphasizing a collaborative 
relation between therapist and patient (Januzzi et al 
2000). Stress management is the essential component 
of cardiac rehabilitation programs, which reduce 
mortality by about 25% (Sommaruga et al. 2008) and 
provide interesting means to identify anxiety in patients 
after an acute coronary syndrome, permitting eventual 
interventions too. This “comprehensive cardiovascular 
rehabilitation” improves psycho-affective conditions, 
self-image, coping capacity, exercise tolerance and 
thus quality of life (Januzzi et al. 2000). It reduces 
some biological risk factors like smoking (Linden et 
al. 1996), and improves significantly HRV (reducing 
also ventricular premature beats) (Tennant and McLean 
2001).
However, can non-pharmacological treatment of 
associated psychiatric conditions ameliorate prognosis 
in heart disease patients? The results of controlled 
clinical trials, which verified in post-acute ischemic 
heart disease patients the impact of stress reduction 
programs, are less congruent. In the Montreal Heart 
Attack Readjustment Trial (M-HART), a program of 
home nursing assistance aimed at stress reduction on 
post-infarction patients, the intervention (probably 
minimal) had a low impact on anxiety symptoms, 
but produced a significant benefit on male mortality 
(showing instead an increased mortality trend on 
women) suggesting, in responders, a beneficial effect 
on outcome, too (Frasure-Smith et al. 1997). Some 
meta-analysis (Linden et al. 1996, Dusseldorp et 
al. 1999) on psycho-social intervention effects in 
heart disease patients showed reduction of systolic 
blood pressure, heart rate, cholesterolemia, and 
even mortality and morbidity. However, there were 
also negative results in the Enhancing Recovery in 
Coronary Heart Disease (ENRICHD) trial (Sheps et al. 
2003), whose primary aim was to determine whether 
non-pharmacological treatment of depression and 
low perceived social support increases reinfarction-
free survival after acute myocardial infarction. In a 
psychological intervention group, a Cochrane review 
showed a significant reduction of myocardial infarction 
incidence (HR 0,78;CI 95% 0,67-0,90), together with 
decreased anxiety symptoms; on the other hand no 
effects were observed for general and cardiovascular 
mortality (Rees et al. 2004). These results, however, 
are unreliable because of trial heterogeneity, different 
bias presence and short follow-up (probably due to 
difficulties in non-pharmacological fundraising). In any 
case, psycho-social interventions should be considered 
an integral part of cardiologic clinical practice. Italian 
cardiologic rehabilitation guidelines (Sommaruga 
et al. 2008) are a valid attempt to formalize needed 
interventions in an optimal program that should include 
educational and psychological interventions (single or 
in group) in order to help patients (and their relatives) 
to recognize and express their emotions regarding the 
disease, apply strategies for lifestyle modification, 
implement correct self-management of treatments and 
recover a satisfying quality of life, encouraging familiar 
and social everyday reintegration.
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heart rate, precludes their use in heart patients (Batelaan 
et al- 2011). They have antimuscarinic properties and 
can behave like class 1A antiarrhythmics, inhibiting 
cardiovascular Na+, Ca2+ and K+channels, often 
leading to life-threatening arrhythmia (Pacher and 
Kecskemeti 2004). They can also, theoretically, 
decrease cardiac contractility and increase myocardial 
irritability.
The traditional irreversible monoamine oxidase 
inhibitor phenelzine has proven efficacy in panic 
disorder, but side effects and the need to follow dietary 
restrictions limit its use (Baldwin 2014).
Anxiolytics
Benzodiazepines are frequently used drugs in 
anxiety disorders (in the United Kingdom in 2010 there 
were 6 million diazepam and lorazepam prescriptions). 
Their principal mode of action involves the interaction 
with a specific site on one of the gamma amino-butyric 
acid receptors that increases the affinity to that inhibitory 
transmitter (Batelaan et al. 2011). Benzodiazepines 
attenuate the response to stress adrenergic activation, 
improving HRV and reducing blood pressure, heart rate 
and myocardial contractility and, probably by direct 
vasodilatation, increasing coronary flow, with possible 
reduction of myocardial oxygen consumption (Batelaan 
et al. 2011). Their fast efficacy and relatively safe side 
effect profile (they can be administered soon after 
myocardial infarction) make them particularly useful to 
treat short-term, transient GAD and panic attacks, rather 
than persistent anxiety disorders. It is only relevant side 
effect is a possible depressive action on respiratory 
centres. In addition, they should not be used in elderly 
patients and in patients with a history of drug-addiction 
or personality disorders, because chronic treatment can 
be complicated by abuse (Batelaan et al. 2011). There is 
documented evidence of adverse effects of the chronic 
use of benzodiazepines and the risk of developing 
addiction in older populations (Benitez et al. 2008). 
However, up to date there are no studies which permit 
a definitive conclusion regarding the relation between 
their administration and cardiovascular events, although 
beneficial effects of these drugs were demonstrated on 
replaced outcomes such as cortisolemia (Meewisse et 
al. 2007), blood pressure and other cardiovascular risk 
factors (cholesterol and glycaemia), perhaps attributable 
to a greater adherence to medical prescription and to 
their positive effect on catecholamine and insulin 
regulation hormone levels.
Combined interventions
A significant decline in the frequency of panic 
attacks was observed during cognitive behavioral 
therapy, SSRI treatment, or both combined (Van 
Apeldoorn et al. 2013).
The MOSAIC (Management of Sadness and 
Anxiety in Cardiology) trial is an ongoing prospective 
randomized trial of a low-intensity intervention 
collaborative care programs, which use care managers 
to assess patients, coordinate care, and perform 
therapeutic interventions for patients hospitalized for 
acute coronary syndrome, heart failure, or arrhythmia, 
and diagnosed with depression, GAD, or panic disorder. 
Compared to enhanced usual care, this will provide data 
regarding whether an intervention that concurrently 
manages these common psychiatric disorders results in 
meaningful improvements in quality of life, psychiatric 
symptoms, and medical outcomes in cardiac patients at 
without known pre-existing heart disease have reported 
no electrocardiographic changes related to their use. In 
contrast, an increased parasympathetic activity, with 
reduction of panic disorder and consequently a drastic 
slowing of sino-atrial node and positive effects on 
HRV, is observed (Batelaan et al. 2011). SSRIs can also 
decrease thrombotic risk, because they reduce platelet 
storage capacity of 5-HT, with potential advantages in 
patients with increased platelet activation like smokers 
(Batelaan et al. 2011). Angina, hypercholesterolemia 
and hypertension are rare side effects of SSRI treatment 
(Katerndahl et al. 2004), although this is controversial 
and not widely accepted. SSRIs, in fact, have actually 
been reported to reduce blood pressure in a large 
scale study when hypertension was comorbid with 
panic disorder (Polyak 2001). Large scale trials of 
drug treatment after an acute myocardial infarction 
(although focused on depression) such as the Sertraline 
Antidepressant Heart Attack Trial (SADHART) did 
not show effects on mortality. However, the results 
suggest that sertraline is a safe treatment in patients 
with a recent myocardial infarction or unstable 
angina, even raising the possibility that it might help 
to prevent recurrent cardiac events (Sheps et al. 2003). 
More recently, however, concerns about cardiac 
problems have led to a reduction in the recommended 
maximum dose of citalopram and escitalopram. In 
overdose, fluoxetine has been reported to cause sinus 
tachycardia, myocardial infarction, junctional rhythms 
and trigeminy and escitalopram QT prolongation and 
bradycardia (van Gorp et al. 2009). Clinicians should 
be more alert with regard to these potential adverse 
reactions and electrocardiogram monitoring may be 
suggested during therapy, especially in patients with 
pre-existing cardiovascular disorders (Pacher and 
Kecskemeti 2004).
SNRIs
SNRIs (such as duloxetine and venlafaxine) 
are a class of drugs used in the treatment of major 
depression and anxiety disorders. They are potent 
inhibitors of serotonin (5-Hydroxytryptamine) and 
norepinephrine reuptake acting on serotonin transporter 
and norepinephrine transporter, and on membrane 
proteins that are responsible for the reuptake of 
serotonin and norepinephrine. Balanced dual inhibition 
of monoamine reuptake can possibly offer advantages 
over other antidepressant drugs by treating a wider 
range of symptoms (Cashman and Ghirmai 2009). 
Venlafaxine, a well established treatment for panic 
disorder (Baldwin 2014), is generally well tolerated, 
with side effects that usually decrease with long-
term treatment (Katzman and Jacobs 2007, Spina et 
al. 2008). However, it shows very strong evidence of 
increasing blood pressure at higher doses, thus blood 
pressure monitoring, particularly in people at risk of 
hypertension and heart disease, is mandatory above 
doses of 150 mg/day. Duloxetine, which has greater 
initial noradrenergic effects and is currently approved in 
many countries for the treatment of GAD, appears to be 
well tolerated, showing limited rates of mild intensity 
side effects (Simon et al. 2009, Dell'Osso et al. 2012).
Other antidepressant drugs
Although these drugs (e.g. amitriptyline, 
clomipramine, desipramine, and imipramine) may be 
effective in panic disorders, their cardiac toxicity, in 
particular secondary to increases in blood pressure or 
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particular attention must be paid to postoperative early 
administration of benzodiazepine, which increases 
delirium risk (Pignay-DeMaria et al. 2003).
Cardiovascular drugs
It has also been suggested that patients with increased 
anxiety sensitivity might benefit from beta-blocker 
treatment (Domschke et al. 2010), as these drugs can 
decrease performance anxiety and at least some of its 
high risk for adverse outcomes (Huffman et al. 2013).
In patients candidate for aortic-coronary bypass, 
preoperative individuation of anxiety symptoms by 
means of structured interview or self-administered 
questionnaire can guide psycho-therapeutic or 
pharmacological interventions, which are efficacious 
in improving anxiety symptoms and significantly 
reducing analgesia, hospital stay and postoperative 
events (Pignay-DeMaria et al. 2003; Vaccarino 
2011). In presence of evident post-surgical stress, 
an early intervention with drugs is opportune, but 
Table I. Classification of Anxiety Disorders according to DSM-5
Disorder Description
Separation Anxiety Disorder It is a psychological condition in which an individual experiences excessive 
anxiety regarding separation from home or from people to whom the individual 
has a strong emotional attachment (e.g. a parent, grandparents, or siblings).
Selective Mutism Consistent failure to speak in specific social situations in which there is an 
expectation for speaking (e.g., at school) despite speaking in other situations
Specific Phobia people with specific phobias, or strong irrational fear reactions, work hard to 
avoid common places, situations, or objects even though they know there's no 
threat or danger. The fear may not make any sense, but they feel powerless to 
stop it. People who experience these seemingly excessive and unreasonable 
fears in the presence of or in anticipation of a specific object, place, or situation 
have a specific phobia.
Social Anxiety Disorder 
(Social Phobia)
It’s the extreme fear of being scrutinized and judged by others in social or 
performance situations: Social anxiety disorder can wreak havoc on the lives of 
those who suffer from it. 
Panic Disorder It is diagnosed in people who experience spontaneous seemingly out-of-the-
blue panic attacks and are preoccupied with the fear of a recurring attack.
Panic Attack (Specifier) The DSM-5 simplified panic attacks as fitting into two simplified types: 
expected or unexpected.
Agoraphobia Some people stop going into situations or places in which they have previously 
had a panic attack in anticipation of it happening again. They typically avoid 
public places where they feel immediate escape might be difficult, such as 
shopping malls, public transportation, or large sports arenas. 
Generalized Anxiety 
Disorder (GAD) 
It is characterized by persistent, excessive, and unrealistic worry about 
everyday things. People experience exaggerated worry and tension, often 
expecting the worst, even when there is no apparent reason for concern. They 
anticipate disaster and are overly concerned about money, health, family, work, 
or other issues. GAD is diagnosed when a person worries excessively about a 
variety of everyday problems for at least 6 months
Substance/Medication-
Induced Anxiety Disorder
When there is evidence that persistent relevant anxiety symptoms have 
physiologically arisen out of use of or withdrawal from either prescribed or 
“recreational” drug use or toxic factors exposition.
Anxiety Disorder Due to 
Another Medical Condition
When there is evidence that persistent, relevant anxiety symptoms have 
physiologically arisen out of a general medical condition.
Other Specified Anxiety 
Disorder
The clinician communicates the specific reason criteria are not met for any 
anxiety disorder within the diagnosis.
Unspecified Anxiety 
Disorder
Unspecified anxiety disorder can be used when the clinician chooses not to 
specify why criteria are not met for an anxiety disorder, for instance, when 
sufficient information is not available to make a diagnosis. 
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Table II. Symptoms in panic disorders and acute coronary syndromes/myocardial ischemia
a) Panic disorders b) Acute coronary syndrome/myocardial 
ischemia
1. Palpitations, pounding heart, or accelerated heart rate
2. Sweating
3. Trembling or shaking
4. Sensations of shortness of breath or smothering
5. Feeling of choking
6. Chest pain or discomfort
7. Nausea or abdominal distress
8. Feeling dizzy, unsteady, lightheaded, or faint
9. Chills or heat sensations
10. Paresthesias (numbness or tingling sensations)
11. Derealization (feelings of unreality) or 
depersonalization (being detached from oneself)
12. Fear of losing control or going crazy
13. Fear of dying
1. palpitation
2. sweating
3. pain (usually it is described like sensation of 
oppression, laceration, burning at precordium that 
can be radiated to neck, shoulders, jowl, arms or 
epigastrium)
4. effort dyspnoea
5. nausea 
6. thoracic pain or discomfort 
7. atypical presentation in diabetic and old patients: 
- fatigue 
- syncope 
- asthenia
- mental confusion
- no symptoms
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physiological effects; also, in such patients, the benefits 
of preventing ventricular arrhythmias and lowering 
heart rate may be particularly important. However, the 
literature about the impact of beta-blockers on anxiety/
anxiety disorders is inconsistent (Bachmann et al. 2011, 
Frasure-Smith et al. 2012). In atrial fibrillation, finally, 
the tendency to fear and catastrophize in response to 
bodily symptoms of anxiety derived a prognostic 
benefit more from rhythm-control than from rate-
control (Frasure-Smith et al. 2012).
Conclusions 
Epidemiological data indicate that anxiety and panic 
disorder show a high prevalence in cardiac patients and 
can influence mortality and morbidity. The association 
between psychopathology and onset of heart disease 
has substantial clinical and public health implications. 
Beyond hard outcomes, psychological and emotional 
disorders produce negative effects on the global 
adjustment. Several pathophysiological alterations, due 
to anxiety disorders seem to be effectively treated with 
proved and safe pharmacological agents in heart patients 
and to decresae risk factors. In any case, improvement 
in quality of life and the comfort of heart patients with 
anxiety comorbidities is an essential clinical objective.
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